Public ‘will not forgive' strike action by resident doctors, says Streeting
It comes after a British Medical Association (BMA) ballot in which resident doctors in England, formerly known as junior doctors, voted to strike over pay, giving them a mandate for action until January 2026.
The Health Secretary wrote in The Times that walkouts would be a 'disaster' for BMA members and patients, saying the Government 'can't afford' pay rises.
He said: 'I urge the BMA, even at this late stage, to reconsider this deeply damaging course of action.
'Work with a government that actually wants to work with you: to improve working conditions for staff and care for patients.
'The public will not forgive strike action in these circumstances and nor will I.'
Some 90% of voting resident doctors backed strike action, with the BMA reporting a turnout of 55%.
The union has said that resident doctors need a pay uplift of 29.2% to reverse 'pay erosion' since 2008/09.
BMA resident doctors committee co-chairs Dr Melissa Ryan and Dr Ross Nieuwoudt said: 'All we need is a credible pay offer and nobody need strike.
'Doctors don't take industrial action lightly – but they know it is preferable to watching their profession wither away.
'The next move is the Government's.'
A Number 10 spokesman said: 'We aren't going to reopen negotiations on pay.
'Resident doctors have received the highest pay award across the public sector for two years in a row, and we've been clear that we can't be more generous than we already have this year.'
Previous strikes by resident doctors and other staff groups saw some 1.5 million appointments, procedures and operations postponed as a result.
The waiting list for routine hospital treatment in England is currently at its lowest level for two years, according to the latest figures, with an estimated 7.39 million treatments waiting to be carried out at the end of April.
Danny Mortimer, chief executive of NHS Employers, which is part of the NHS Confederation, said: 'Further strikes are the last thing health leaders wanted and could result in tens, if not hundreds, of thousands of operations and procedures being delayed or cancelled, leaving patients in pain or discomfort.'
Daniel Elkeles, chief executive of NHS Providers, said: 'A return to industrial action would be a huge setback – bad for patients, for staff and for the NHS.'
In September, BMA members voted to accept a Government pay deal worth 22.3% on average over two years.
And the 2025/26 pay deal saw resident doctors given a 4% uplift plus £750 'on a consolidated basis' – working out as an average pay rise of 5.4%.
The BMA call for a 29.2% uplift is based on Retail Prices Index (RPI) inflation, the measure of average changes in the price of goods and services used by most households.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Glasgow hospice funding plea as it reveals £755k shortfall
A GLASGOW hospice has begun a fundraising campaign after revealing it faces a shortfall of more than three quarters of a million pounds. The Prince and Princess of Wales Hospice in Bellahouston Park is hoping 'the local community' will support its Vital Care Appeal. Chief Executive Rhona Baillie said: 'We provide free specialist palliative and end-of-life care to 1200 new patients and their families each year, both at the hospice at Bellahouston Park and in patients' own homes. 'We're doing everything we can to keep our costs to a minimum. We run our services efficiently, we're innovating with our fundraising, and we make every pound count. 'But despite our efforts, a significant funding gap remains.' (Image: Colin Mearns/Newsquest) The hospice is predicting a £755,000 shortfall in funding, citing the rise in demand for its services, patients' more complex needs and rising costs as the main pressures. Ms Baillie said that 'with local government funding just 30 per cent of running the hospice, the remaining 70 per cent comes from fundraising and donations' and added: 'We're not in crisis yet, but we need to act and that's why we are turning to our friends in the community for help.' Kirsty with her dad, Robert (Image: PPWH) Kirsty Dolan, 22, is supporting the appeal following the death of her dad, Robert, in the hospice in 2021. Robert was diagnosed with Parkinson's when he was 48 and Kirsty, who was only 10 at the time, along with her mum and older sister, became carers for him. In 2021, he visited the hospital for inpatient care. READ NEXT: Seeds of trees which survived Hiroshima help create new Glasgow garden Glasgow pupil heading for top art school after exam success 'We'll use King's Honours to keep battling for our Glasgow community' 'He had developed supranuclear palsy and needed specialist care,' said Kirsty. 'He was in the IPU for about a week where he just received the very best care you could imagine. 'We got to spend as much time with him as we could, and we even got to bring our dogs in for a visit. When he was nearing the end of his life, we all stayed over at the hospice in the family rooms so we could be close.' Kirsty also received support from the hospice's Family Support Service. 'I was really struggling,' she said. 'I was at breaking point. I emailed the hospice and the Family Support Service got in touch – and I have to say, it changed my life. "The team worked with me over a period of time and just helped me see things differently. ' It really was a lifeline, and I needed that support so much.' Glasgow Times readers helped raise the £21m needed for the new hospice, which opened in 2018, through our Brick by Brick Appeal. For more information on the Vital Care Appeal visit or call 0141 726 2660.
Newsweek
2 hours ago
- Newsweek
Donald Trump Threatens 250% Tariff on Pharmaceuticals
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has said that tariffs on pharmaceutical imports could eventually reach up to 250 percent, as his administration works to lower prescription prices for Americans. During an interview with CNBC on Tuesday, the president said he will initially impose a "small tariff on pharmaceuticals," which will rise to 150 percent "in one year, one and a half years maximum," before then eventually jumping to 250 percent. Newsweek reached out to the White House via email for comment. Why It Matters The United States imports a significant amount of pharmaceuticals each year—over $200 billion in 2024, according to the Observatory of Economic Complexity. Should Trump follow through on ramping up these duties, the highest he has threatened on the industry to date, experts believe this could result in significant increases to drug prices in the U.S. However, some health policy experts told Newsweek this could also help rebalance the global drug supply chain to better favor American customers. What To Know Trump said that the tariffs are intended to encourage pharmaceutical companies to move their operations to the U.S.—"because we want pharmaceuticals made in our country"—and to minimize reliance on Europe. He had previously threatened to place 200 percent tariffs on pharmaceuticals in July, but said he would give the industry time before this change came into effect. Trump's threats of pharmaceutical tariffs have raised concerns among experts that these could lead to increased costs and medication shortages in the U.S. In April, the UNC Center for the Business of Health published a report warning that these effects would be especially significant for generic drugs, which are more likely to be imported and operate on lower profit margins than brand-name medications. "A 250 percent tariff on pharmaceuticals would have a significant impact on drug prices," said health economist Jeromie Ballreich. Ballreich told Newsweek that, for branded pharmaceuticals, higher costs from the tariffs will be "passed on to consumers and most likely will be indirect through higher prescription drug insurance premiums." Major pharmaceutical companies across the world saw their shares fall on Wednesday following Trump's announcement. England-based AstraZeneca was down by 1.1 percent, Indiana-based Eli Lilly by 2.3 percent, and Germany-based Bayer AG by nearly 10 percent as of 11:20 ET. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, 2025. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, latest threat comes as the industry braces for the outcome of an ongoing probe by the Commerce Department into the national security implications of America's medicinal imports. The investigation was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Trump did not provide many specifics, such as whether certain classes of pharmaceuticals would be exempt, beyond stating that these tariffs are separate from the country-specific duties that came into effect last week. However, the announcement appears to contradict the terms of the European Union deal struck in July, which the European Commission president said placed a 15-percent tariff "ceiling" on multiple sectors, including pharmaceuticals. Experts had already warned that the 15 percent tariff outlined in the EU trade deal could end up costing the pharmaceutical industry billions. The cost implications could also be seen as conflicting with the administration's separate attempts to lower the price of prescription drugs. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, 2025. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, May, Trump signed an executive order directing the Secretary of Commerce and U.S. Trade Representative to "ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States." It also proposed that the U.S. be given Most-Favored-Nation (MFN) status, which would require drug companies to offer Americans the same lowest price that drugs are sold for in other countries. Trump followed this up by sending letters to 17 of the world's largest pharmaceutical companies on July 31, outlining steps they must take within 60 days to lower prescription prices for U.S. customers. These include extending MFN pricing to Medicaid, guaranteeing MFN pricing for new medications and negotiating "harder with foreign freeloading nations." The letters also call on the companies to expand direct-to-consumer distribution models to ensure customers "get the same low MFN prices that manufacturers already offer to third-party payers." "At face value, these tariffs are contradictory to his efforts to lower domestic prices," Ballreich told Newsweek. "However, if the tariffs are used as a threat to get drug companies to comply to his administration's [executive orders], including the recent letters to pharmaceutical CEOs, then I think we could see some changes to the pharmaceutical market, which will lower domestic drug prices." Several drugmakers, including Eli Lilly, AstraZeneca and Johnson & Johnson, have also pledged to expand their U.S. manufacturing presence. Prior to the letters being sent, but amid this pressure from the administration, a number had also announced they would be reducing some U.S. drug prices. Health policy analyst Mariana Socal warned that beyond potential cost implications, the tariffs could significantly disrupt the drug development pipeline, potentially jeopardizing the release of new medications. "Aside from the problem of added costs, the uncertainty introduced by tariff policies is detrimental in and of itself to the pharmaceutical market," she told Newsweek, noting that only around one in 10,000 investigated compounds make it to pharmacy shelves, and only do so after decades of work. "Any added uncertainty is likely to be detrimental to this industry, including disincentivizing investors from supporting this industry and pharmaceutical manufacturers from continuing to look for cures," she said. What People Are Saying Health economist Jeromie Ballreich told Newsweek: "This tariff could really disrupt the U.S. prescription drug market, especially the Medicare part D market, where the party plans will be on the hook for the higher price prices and result in significant premium increases to offset these higher prices. Given that, I don't think it's likely that this massive tariff will occur, but rather is a threat to force companies to find solutions based on the executive orders and his recent letters to pharmaceutical CEOs." Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, told Newsweek: "It is critical to continue to identify solutions to lower drug prices in America and improve drug affordability for Americans. However, it is unclear how tariffs would advance affordability. On the opposite, tariffs can be understood as a hidden tax." "In the short term, the likelihood that added costs from tariffs will be passed through to consumers can be reduced by existing contractual agreements with supply chain participants such as distributors and group purchasing organizations, which can protect buyers from price increases for 1-3 years," she added. "However, even if the added cost of tariffs would not necessarily be passed-through to patients in the short term, it could raise costs in the long run." What Happens Next On Sunday, Trump said he would be announcing tariffs on the industry "within the next week or so."
